[1]冯钰强,李 文.基于血细胞参数形成的新型比值在慢性阻塞性肺疾病中的研究价值[J].医学信息,2025,38(08):187-192.[doi:10.3969/j.issn.1006-1959.2025.08.040]
 FENG Yuqiang,LI Wen.Research Value of Novel Ratios Based on Blood Cell Parameters in Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2025,38(08):187-192.[doi:10.3969/j.issn.1006-1959.2025.08.040]
点击复制

基于血细胞参数形成的新型比值在慢性阻塞性肺疾病中的研究价值()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年08期
页码:
187-192
栏目:
综述
出版日期:
2025-04-15

文章信息/Info

Title:
Research Value of Novel Ratios Based on Blood Cell Parameters in Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959(2025)08-0187-06
作者:
冯钰强1李 文2
1.广东医科大学第一临床医学院,广东 湛江 524000;2.广东医科大学附属医院呼吸与危重症医学科,广东 湛江 524000
Author(s):
FENG Yuqiang1 LI Wen2
1.The First Clinical Medical College of Guangdong Medical University, Zhanjiang 524000, Guangdong, China;2.Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, Guangdong, China
关键词:
慢性阻塞性肺疾病血细胞参数生物标志物
Keywords:
Chronic obstructive pulmonary disease Blood cell parameters Biomarkers
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2025.08.040
文献标志码:
A
摘要:
慢性阻塞性肺疾病(COPD)是一种具有持续性呼吸道症状和不完全可逆性气流受限的疾病,广泛认可的COPD发病机制是免疫失衡和炎症假说,动态监测炎症指标及免疫功能的变化对指导临床治疗有着重要意义。多项研究证实,全血细胞计数参数衍生的简便新型生物标志物在评估COPD患者的疾病严重程度和预后方面发挥着不可替代的关键作用。本文通过回顾近年来有关血细胞计数比值在COPD发生和住院不良预后之间的相关研究进行综述,以期为COPD治疗和干预提供更具针对性的策略。
Abstract:
Chronic obstructive pulmonary disease (COPD) is a disease characterized by persistent respiratory symptoms and partially reversible airflow limitation. The widely accepted mechanism of COPD is the imbalance of immunity and the hypothesis of inflammation. Dynamic monitoring of inflammation markers and changes in immune function plays an important role in guiding clinical treatment. Numerous studies have confirmed that novel biomarkers derived from blood cell count parameters play an irreplaceable key role in evaluating the severity and prognosis of COPD patients. This article reviews the recent studies on the relationship between the ratio of blood cell count and the occurrence of COPD and the poor prognosis of hospitalization, in order to provide more targeted strategies for the treatment and intervention of COPD.

参考文献/References:

[1]Christenson SA,Smith BM,Bafadhel M,et al.Chronic obstructive pulmonary disease[J].The Lancet,2022,399(10342):2227-2242.[2]Chaurasia SN,Kushwaha G,Kulkarni PP,et al.Platelet HIF-2α promotes thrombogenicity through PAI-1 synthesis and extracellular vesicle release[J].Haematologica,2019,104(12):2482-2492.[3]Shao S,Zhang Z,Feng L,et al.Association of Blood Inflammatory Biomarkers with Clinical Outcomes in Patients with AECOPD:An 8-Year Retrospective Study in Beijing[J].International Journal of Chronic Obstructive Pulmonary Disease,2023,18:1783-1802.[4]Xiong W,Xu M,Zhao Y,et al.Can we predict the prognosis of COPD with a routine blood test?[J].International Journal of Chronic Obstructive Pulmonary Disease,2017,12:615-625.[5]Forget P,Khalifa C,Defour JP,et al.What is the normal value of the neutrophil-to-lymphocyte ratio?[J].BMC Research Notes,2017,10(1):12.[6]Forget P,Teng F,Ye H,et al.Predictive value of neutrophil to lymphocyte ratio in patients with acute exacerbation of chronic obstructive pulmonary disease[J].PLoS One,2018,13(9):e0204377.[7]Liu J,Liu J,Zou Y.Relationship between neutrophil–lymphocyte ratio and short-term prognosis in the chronic obstructive pulmonary patients with acute exacerbation[J].Bioscience Reports,2019,39(5):BSR20190675.[8]Luo Z,Zhang W,Chen L,et al.Prognostic Value of Neutrophil:Lymphocyte and Platelet:Lymphocyte Ratios for 28-Day Mortality of Patients with AECOPD[J].International Journal of General Medicine,2021,14:2839-2848.[9]Gómez-Rosero JA,Cáceres-Galvis C,Ascuntar J,et al.Biomarkers as a Prognostic Factor in COPD Exacerbation:A Cohort Study[J].COPD,2021,18(3):325-332.[10]Emami Ardestani M,Alavi-Naeini N.Evaluation of the relationship of neutrophil‐to lymphocyte ratio and platelet‐to‐lymphocyte ratio with in‐hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease[J].The Clinical Respiratory Journal,2020,15(4):382-388.[11]Yao C,Liu X,Tang Z.Prognostic role of neutrophil–lymphocyte ratio and platelet–lymphocyte ratio for hospital mortality in patients with AECOPD[J].International Journal of Chronic Obstructive Pulmonary Disease,2017,12:2285-2290.[12]Eraslan Doganay G,Cirik MO.Are Neutrophil-Lymphocyte,Platelet-Lymphocyte,and Monocyte-Lymphocyte Ratios Prognostic Indicators in Patients With Chronic Obstructive Pulmonary Disease in Intensive Care Units?[J].Cureus,2022,14(3):e23499.[13]Singh B,Kampani G,Lall B,et al.Study of Inflammatory Markers in Chronic Obstructive Pulmonary Disease[J].Journal of the Association of Physicians of India,2022,70(12):48-52.[14]Wang H,Yang T,Yu X,et al.Risk Factors for Length of Hospital Stay in Acute Exacerbation Chronic Obstructive Pulmonary Disease:A Multicenter Cross-Sectional Study[J].International Journal of General Medicine,2022,15:3447-3458.[15]Mallah H,Ball S,Sekhon J,et al.Platelets in chronic obstructive pulmonary disease:An update on pathophysiology and implications for antiplatelet therapy[J].Respiratory Medicine,2020,171:106098.[16]Lefran?觭ais E,Ortiz-Mu?觡oz G,Caudrillier A,et al.The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors[J].Nature,2017,544(7648):105-109.[17]Yao C,Wang L,Shi F,et al.Optimized combination of circulating biomarkers as predictors of prognosis in AECOPD patients complicated with Heart Failure[J].International Journal of Medical Sciences,2021,18(7):1592-1599.[18]Kumar P,Law S,Sriram KB.Evaluation of platelet lymphocyte ratio and 90-day mortality in patients with acute exacerbation of chronic obstructive pulmonary disease[J].Journal of Thoracic Disease,2017,9(6):1509-1516.[19]Liu X,Ge H,Feng X,et al.The Combination of Hemogram Indexes to Predict Exacerbation in Stable Chronic Obstructive Pulmonary Disease[J].Frontiers in Medicine,2020,7:572435.[20]Zinellu A,Paliogiannis P,Sotgiu E,et al.Platelet Count and Platelet Indices in Patients with Stable and Acute Exacerbation of Chronic Obstructive Pulmonary Disease:A Systematic Review and Meta-Analysis[J].COPD,2021,18(2):231-245.[21]Zuo H,Xie X,Peng J,et al.Predictive Value of Novel Inflammation-Based Biomarkers for Pulmonary Hypertension in the Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Analytical Cellular Pathology,2019,2019:1-9.[22]Mirestean CC,Stan MC,Iancu RI,et al.The Prognostic Value of Platelet–Lymphocyte Ratio,Neutrophil–Lymphocyte Ratio,and Monocyte–Lymphocyte Ratio in Head and Neck Squamous Cell Carcinoma (HNSCC)—A Retrospective Single Center Study and a Literature Review[J].Diagnostics (Basel),2023,13(22):3396.[23]Vakhshoori M,Nemati S,Sabouhi S,et al.Prognostic impact of monocyte-to-lymphocyte ratio in coronary heart disease:a systematic review and meta-analysis[J].Journal of International Medical Research,2023,51(10):3000605231204469.[24]Li Q,Ma X,Shao Q,et al.Prognostic Impact of Multiple Lymphocyte-Based Inflammatory Indices in Acute Coronary Syndrome Patients[J].Frontiers in Cardiovascular Medicine,2022,9:811790.[25]Dukic V,Mur?觢ic D,Popovic Grle S,et al.Monocyte related haematological indices in acute exacerbations of COPD – a new biomarker?[J].Monaldi Archives for Chest Disease,2023,94(3).[26]Long J,Xu P,Chen J,et al.Inflammation and comorbidities of chronic obstructive pulmonary disease:The cytokines put on a mask![J].Cytokine,2023,172:156404.[27]Tong YS,Tan J,Zhou XL,et al.Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer[J].Journal of Translational Medicine,2017,15(1):221.[28]Liu B,Wang J,Li YY,et al.The association between systemic immune-inflammation index and rheumatoid arthritis:evidence from NHANES 1999–2018[J].Arthritis Research & Therapy,2023,25(1):34.[29]Sakurai K,Chubachi S,Irie H,et al.Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients[J].BMC Pulmonary Medicine,2018,18(1):65.[30]Xu Y,Yan Z,Li K,et al.The association between systemic immune-inflammation index and chronic obstructive pulmonary disease in adults aged 40 years and above in the United States:a cross-sectional study based on the NHANES 2013–2020[J].Frontiers in Medicine,2023,10:1270368.[31]Benz E,Wijnant SRA,Trajanoska K,et al.Sarcopenia,systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma:a population-based study[J].ERJ Open Research,2022,8(1):00628-2021.[32]Guang Y,Jie Z,Feng D,et al.Surrogate scale for evaluating respiratory function based on complete blood count parameters[J].Journal of Clinical Laboratory Analysis,2018,32(5):e22385.[33]Huang Y,Wang J,Shen J,et al.Relationship of Red Cell Index with the Severity of Chronic Obstructive Pulmonary Disease[J].International Journal of Chronic Obstructive Pulmonary Disease,2021,16:825-834.[34]Shi Y,Shi Y,Xu Z,et al.Association of Red Cell Index and Hospital Mortality in Chronic Obstructive Pulmonary Disease Patients Admitted to the Intensive Care Unit:A Retrospective Cohort Study[J].International Journal of Chronic Obstructive Pulmonary Disease,2023,18:2267-2276.[35]Yuan FZ,Shui W,Xing YL,et al.Association of Red Cell Index and Adverse Hospitalization Outcomes in Chronic Obstructive Pulmonary Disease Patients with Acute Exacerbation:A Retrospective Cohort Study[J]. International Journal of Chronic Obstructive Pulmonary Disease,2022,17:2263-2275.[36]El-Gazzar AG,Kamel MH,Elbahnasy OKM,et al.Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients[J].Expert Review of Respiratory Medicine,2019,14(1):111-116.[37]Rahimirad S,Ghaffary MR,Rahimirad MH,et al.Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease[J].Tuberkuloz ve Toraks,2017,64(1):25-31.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
 ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(08):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
 CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(08):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
 WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(08):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
 LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(08):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
 LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(08):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
 ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(08):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
 JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(08):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
 ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(08):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
 ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]

更新日期/Last Update: 1900-01-01